Yasmin review extension
This article was originally published in Pharmaceutical Approvals Monthly
FDA's user fee deadline for a low-dose version of Schering AG's oral contraceptive Yasmin (ethinyl estradiol/drospirenone) is Nov. 16 following a three-month review extension. "According to the FDA's written notification to [U.S. subsidiary] Berlex…the extension 'will provide time for a full review' of the application," Schering AG reported July 19. The firm said it "is confident in a 2005 launch" for the product, which contains 0.02 mg of estradiol compared to 0.03 mg in currently available Yasmin. A 2004 launch was projected at the time of the October 2003 filing...
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.